See Full STXS Report below….

About Broad Street Alerts:

Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our

Members in the last 3 small cap alerts alone!

• February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%
• March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members
• March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.

These are numbers that make traders drool. Any trader in any market would fall all over themselves to

see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and

verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest

of the small-cap newsletters as the best in business. We know with a large following comes a large

responsibility as we have everyone from institutional investors to the beginner following our profiled

securities in our newsletters. This is something we take very seriously always seeking small cap growth

companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time.

We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

 

The stock of Stereotaxis Incorporated (NASDAQ:STXS) registered a decrease of 17.98% in short interest. STXS’s total short interest was 482,700 shares in March as published by FINRA. Its down 17.98% from 588,500 shares, reported previously. With 57,600 shares average volume, it will take short sellers 8 days to cover their STXS’s short positions. The short interest to Stereotaxis Incorporated’s float is 2.84%. The stock closed at $1.1 during the last session. It is down 52.78% since August 24, 2015 and is uptrending. It has outperformed by 43.76% the S&P500.

Stereotaxis, Inc. designs, makes and markets robotic systems and instruments for use primarily by electrophysiologists for the treatment of abnormal heart rhythms known as cardiac arrhythmias. The company has a market cap of $24.24 million. The Firm offers its Epoch Solution, a remote robotic navigation system for use in a hospital’s interventional surgical suite or interventional lab. It currently has negative earnings. The Epoch Solution consists of the Niobe ES Robotic Magnetic Navigation System (Niobe ES system), Odyssey Information Management Solution (Odyssey Solution) and the Vdrive Robotic Navigation System (Vdrive system).

The institutional sentiment decreased to 0.57 in 2015 Q3. Its down 0.65, from 1.22 in 2015Q2. The ratio worsened, as 6 funds sold all Stereotaxis Inc shares owned while 8 reduced positions. 5 funds bought stakes while 3 increased positions. They now own 2.86 million shares or 17.49% less from 3.47 million shares in 2015Q2.

Dafna Capital Management Llc holds 1.26% of its portfolio in Stereotaxis Inc for 1.37 million shares. Perkins Capital Management Inc owns 23,000 shares or 0.02% of their US portfolio. Moreover, American International Group Inc has 0% invested in the company for 2,000 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Bank Of New York Mellon Corp, a New York-based fund reported 11,692 shares.

 

 

 

 

 

Early adopter of Stereotaxis Niobe system passes 1,000-procedure mark; shares up 50%

 

Thinly traded nano cap Stereotaxis (STXS +49.5%) announces that an early adopter of its Niobe remote magnetic navigation system, Hartford, CT-based Hoffman Heart and Vascular Institute at Saint Francis Hospital and Medical Center, recently completed its 1,000th cardiac ablation procedure. The facility is the company’s top user of its technology in New England.

Niobe enables the physician to better visualize and control an ablation catheter.

Shares are up on a 40x surge in volume.

Now read Stereotaxis – Interview of Experienced Doctor With Stereotaxis’ Robotic System 

Sources- Seeking Alpha

Source- Yahoo finance

Source: riversidegazette

Source- BroadStreetAlerts

 

Broad street Alerts has not been compensated for this article and we do not hold any positions in STXS

See Full Report below….

 

About Broad Street Alerts:

 

Big opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our

Members in the last 3 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49%

 

for our members.

 

 

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to

see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and

verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest

of the small-cap newsletters as the best in business. We know with a large following comes a large

responsibility as we have everyone from institutional investors to the beginner following our profiled

securities in our newsletters. This is something we take very seriously always seeking small cap growth

companies that have both near and long-term potential for our members.

 

***Get our small cap profiles, special situation and watch alerts in real time.

We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Report:

While new World Heavyweight Champion Roman Reigns celebrates his new title, World Wrestling Entertainment, Inc. (NYSE:WWE) shareholders are celebrating a record attendance for last night’s Wrestlemania 32. The stock is 4.8% higher at $18.14 — though the shares remain in the $16-$19 range that’s mostly contained them since early November. Elsewhere, options volume is soaring, and it appears traders are skeptical of WWE’s rally.
By the numbers, more than 6,400 WWE put options have crossed — eight times the expected intraday volume. Most of the action has taken place at the April and May 18 strikes. All signs point to the initiation of long positions, meaning traders are betting on the shares falling back below $18 before the expiration dates at the close on Friday, April 15, and Friday, May 20.

This activity goes against what’s normally seen from the stock’s options traders. For instance, WWE’s 10-day call/put volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) comes in at 3.20 — in the 72nd percentile of its annual range. The stock’s Schaeffer’s put/call volume ratio (SOIR) of 1.12 echoes this call-focused approach, too, since it’s lower than 86% of readings from the past year.

Outside the options pits, WWE has attracted heavy pessimism ahead of this afternoon’s post-Wrestlemania conference call. In fact, at 8.9 million shares, short interest on the stock is now at an all-time high. Even more shocking, it’d take these bears over 19 sessions to buy back their positions, at average daily volumes.

As mentioned, World Wrestling Entertainment, Inc. (NYSE:WWE) has mostly traded within a tight $3 range during the past few months. Looking back further, though, the shares have gained almost 36% in the past 12 months. What’s more, WWE’s recent pullbacks have been contained by the stock’s 60-day moving average.

 

Source: Schaeffer’s Investment Research

Broad Street Alerts has not been compensated for the mention of _WWE__ and we do not hold any positions.

See Full Report below….

 

About Broad Street Alerts:

 

Big opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our

Members in the last 3 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49%

 

for our members.

 

 

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to

see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and

verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest

of the small-cap newsletters as the best in business. We know with a large following comes a large

responsibility as we have everyone from institutional investors to the beginner following our profiled

securities in our newsletters. This is something we take very seriously always seeking small cap growth

companies that have both near and long-term potential for our members.

 

***Get our small cap profiles, special situation and watch alerts in real time.

We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Report:

JMP Securities reissued their buy rating on shares ofIntercept Pharmaceuticals Inc (NASDAQ:ICPT) in a research note issued to investors on Wednesday,Market Beat.com reports. They currently have a $200.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also recently issued reports on the company. Morgan Stanley upgraded Intercept Pharmaceuticals from an underweight rating to an equal weight rating and set a $100.00 target price for the company in a report on Friday, January 29th. Needham & Company LLC reissued a buy rating and issued a $500.00 price objective on shares of Intercept Pharmaceuticals in a report on Wednesday, January 27th. Cowen and Company restated an outperform rating and set a $212.00 price objective on shares of Intercept Pharmaceuticals in a research report on Tuesday, March 8th. Goldman Sachs began coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, March 30th. They set a neutral rating and a $114.00 target price on the stock. Finally, Barclays decreased their target price on shares of Intercept Pharmaceuticals from $300.00 to $200.00 and set an overweight rating on the stock in a report on Wednesday, February 24th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $253.30.

In other news, insider Lisa Bright sold 241 shares of the stock in a transaction that occurred on Thursday, February 25th. The stock was sold at an average price of $115.22, for a total value of $27,768.02. Following the completion of the sale, the insider now directly owns 19,259 shares of the company’s stock, valued at $2,219,021.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

A number of hedge funds and institutional investors have modified their holdings of the company. CenturyLink Investment Management Co increased its position in shares of Intercept Pharmaceuticals by 94.6% in the fourth quarter. CenturyLink Investment Management Co now owns 2,092 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 1,017 shares during the last quarter. Profund Advisors LLC boosted its stake in shares of Intercept Pharmaceuticals by 0.5% in the fourth quarter. Profund Advisors LLC now owns 12,113 shares of the biopharmaceutical company’s stock worth $1,809,000 after buying an additional 65 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Intercept Pharmaceuticals by 1.7% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 12,310 shares of the biopharmaceutical company’s stock worth $1,847,000 after buying an additional 200 shares during the last quarter. Bellevue Asset Management AG boosted its stake in shares of Intercept Pharmaceuticals by 55.2% in the fourth quarter. Bellevue Asset Management AG now owns 13,500 shares of the biopharmaceutical company’s stock worth $2,016,000 after buying an additional 4,800 shares during the last quarter. Finally, Polar Capital LLP boosted its stake in shares of Intercept Pharmaceuticals by 3.4% in the fourth quarter. Polar Capital LLP now owns 13,921 shares of the biopharmaceutical company’s stock worth $2,079,000 after buying an additional 462 shares during the last quarter.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 4.914% during mid-day trading on Wednesday, reaching $137.185. The company’s stock had a trading volume of 426,692 shares. Intercept Pharmaceuticals has a one year low of $89.76 and a one year high of $314.88. The company’s market capitalization is $3.34 billion. The stock has a 50-day moving average price of $121.40 and a 200-day moving average price of $147.14.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Tuesday, February 23rd. The biopharmaceutical company reported ($3.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.15) by $0.47. The firm earned $0.45 million during the quarter, compared to analyst estimates of $0.43 million. During the same quarter in the prior year, the company posted ($1.63) EPS. Intercept Pharmaceuticals’s revenue was up .4% on a year-over-year basis. Equities research analysts forecast that Intercept Pharmaceuticals will post ($15.73) EPS for the current year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company’s product candidate, obeticholic acid (NASDAQ:ICPT), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Source: IRA Market Report

Broad Street Alerts has not been compensated for the mention of _ICPT__ and we do not hold any positions.

See Full Report below….

 

About Broad Street Alerts:

 

Big opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our

Members in the last 3 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49%

 

for our members.

 

 

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to

see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and

verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest

of the small-cap newsletters as the best in business. We know with a large following comes a large

responsibility as we have everyone from institutional investors to the beginner following our profiled

securities in our newsletters. This is something we take very seriously always seeking small cap growth

companies that have both near and long-term potential for our members.

 

***Get our small cap profiles, special situation and watch alerts in real time.

We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Report:

Zafgen Inc. (Nasdaq: ZFGN) announced new data from the bestPWS ZAF-311 study, a pivotal, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of beloranib, a MetAP2 inhibitor, in patients with Prader-Willi syndrome (PWS) during the six-month randomized treatment period. Data presented today during ENDO 2016, the Endocrine Society’s 98th Annual Meeting & Expo, showed that beloranib was associated with improvement in total cholesterol, LDL cholesterol and other cardiometabolic risk factors, and a reduction in fat mass when compared to placebo.

As previously reported, the bestPWS study achieved its co-primary efficacy endpoints, as beloranib demonstrated a statistically significant reduction in both body weight and hyperphagia-related behaviors, making it the first investigational drug to demonstrate a positive impact on these two hallmark challenges of PWS.

“These data further support the efficacy profile of beloranib in PWS, and advance our understanding of the potential of our MetAP2 inhibitor platform to impact metabolic disorders,” stated Thomas Hughes, Ph.D., Chief Executive Officer of Zafgen. “We believe these data also provide greater perspective on the benefit/risk relationship of beloranib in this high-risk patient population and we look forward to discussing these results with the FDA.”

PWS is the most common genetic cause of life-threatening obesity. Hyperphagia, pathologic hunger-related behaviors, dominates the lives of individuals with PWS, driving patients to engage in problematic behaviors which can lead to bodily injury, choking, and stomach rupture. Patients with PWS also have higher rates of psychiatric conditions including aggression, anxiety and psychosis. Compounding the obesity in PWS is markedly low metabolism, abnormal body composition with higher fat mass and low lean mass, and higher risk for cardiopulmonary and metabolic co-morbidities, all of which contribute to a higher risk of obesity-related mortality.

“Prader-Willi syndrome is a life-limiting and life-threatening condition with no available treatment options that significantly impact affected individuals and their families,” said Merlin G. Butler, M.D., Ph.D., FFACMG, Professor of Psychiatry, Behavioral Sciences and Pediatrics, Director, Division of Research and Genetics, Departments of Psychiatry & Behavioral Sciences and Pediatrics at the University of Kansas Medical Center. “In addition to the reduction in body weight and decrease in excessive eating behaviors previously reported from this study, the data presented today demonstrate important reductions in cardiometabolic risk factors and further support a strong rationale for continued evaluation of beloranib as a potential treatment for PWS.”

BestPWS ZAF-311 Efficacy and Safety Results

In the bestPWS ZAF-311 study, 107 patients were randomized to receive twice-weekly subcutaneous injections of either 2.4 mg or 1.8 mg of beloranib or placebo. Seventy-four patients completed the full 26 weeks of treatment per the study protocol, and 27 patients completed at least 75 percent of the randomized treatment period prior to the suspension of dosing in the trial in October 2015. There were six patients who discontinued early. The co-primary efficacy endpoints for this trial were improvement in hyperphagia-related behaviors and reduction in body weight. Secondary endpoints in this trial included improvement in total body fat mass and improvement in lipids and markers of cardiometabolic risk (TC and LDL). Patients in the trial were on average 20 years old, had an average BMI of 40 kg/m2, an average body weight of 100 kg, an average fat mass of 51 kg and an average hyperphagia total score of 16.9, consistent with moderate to severe hyperphagia, at the beginning of randomized treatment. These baseline characteristics were well-balanced across treatment arms. In agreement with the FDA, Zafgen has analyzed the data using a mixed model repeated measures (MMRM) approach to account for missing endpoint data from the patients who did not complete the randomized treatment period of the trial.

Co-primary Endpoints

	Average Weight atBaseline (kg)1	PercentChange inBody Weight1			Placebo-adjustedChange inBody Weight1			p-value
2.4 mg beloranib (n=37)	105.7		-5.30	%		-9.45	%	<0.0001
1.8 mg beloranib (n=36)	97.5		-4.05	%		-8.20	%	<0.0001
Placebo (n=34)	100.9		+4.15	%

1Endpoint results shown are Least Squares mean values.

Patients in the ZAF-311 trial were markedly obese at baseline. Patients randomized to receive placebo displayed substantial (4.15%) increase in body weight over the course of the six months of randomized treatment. Body weight gain in this patient population was anticipated, and typically occurs throughout life generally due to a lack of effective treatments for managing obesity. Patients treated with beloranib, in contrast to placebo, experienced a reduction in weight, with the 2.4 mg dose arm displaying a 5.3 percent reduction from baseline, with a placebo-adjusted weight loss of 9.45 percent.

	Average HyperphagiaQuestionnaire(HQ-CT)Total Score at Baseline	Unit Change inHQ-CT TotalScore1	Placebo-adjusted Change inHQ-CT TotalScore1	p-value
2.4 mg beloranib (n=37)	18.3	-7.4	-7.0	0.0001
1.8 mg beloranib (n=36)	17.4	-6.7	-6.3	0.0003
Placebo (n=34)	15.0	-0.4

1Endpoint results shown are Least Squares mean values.

The HQ-CT is a PWS-specific study instrument that provides an assessment by caregivers of the food-seeking behaviors exhibited by patients. The scale provides a composite value from nine questions, each rated on a scale of zero to four units (total range of score of zero to 36). Patients in the ZAF-311 trial were enrolled only if their baseline HQ-CT total score was greater than 12 units, representing moderate-to-severe hyperphagia related behaviors at baseline. While hyperphagia-related behaviors were stable over six months of treatment in the placebo arm, both the 2.4 mg and 1.8 mg beloranib arms showed highly statistically significant reductions in HQ-CT total score, indicative of reduced hunger-associated behaviors.

Secondary Endpoints In this study, beloranib was associated with improvements in total cholesterol and LDL cholesterol as well as other markers of cardiometabolic risk compared to placebo. The mean change in HDL cholesterol and triglycerides showed no significant change from baseline for each treatment arm. The reduction in leptin levels and increase in adiponectin levels seen in PWS patients receiving both dose levels of beloranib is consistent with altered fatty acid mobilization and lipid utilization.

	Change inLDLCholesterol(mg/dl)1	Change inTotalCholesterol(mg/dl)1	Change inLeptin(μg/L)1	Change inAdiponectin(μg/L)1	PercentChange inCRP2
Mean at Baseline	101	174	6.9	4.6	7.6 μg/mL
2.4 mg beloranib (n=37)	-17.8**	-18.0*	-24.0**	+1.9**	-53%**
1.8 mg beloranib (n= 36)	-16.6**	-17.2*	-20.7**	+1.7**	-56%**
Placebo (n=34)	+1.8	+1.3	+6.9	-0.5		+2.5	%

1Endpoint results shown are Least Squares mean values.2Endpoint results are Geometric Least Squares mean values.*p<0.001 compared to placebo** p<0.0001 compared to placebo

Body composition was measured using dual-energy X-ray absorptiometry (DXA) scan. Patients treated with beloranib demonstrated a significant reduction in total body mass and fat mass at both the 1.8 mg and 2.4 mg doses of beloranib. Lean body mass was minimally changed from baseline with a 0.5 kg loss in the 1.8 mg beloranib arm, a 0.7 kg loss in the 2.4 mg beloranib arm and an increase of 0.7 kg in the placebo arm. Approximately 90 percent of loss in total body mass with beloranib was due to loss of body fat, indicating preferential loss of fat with minimal change in lean mass.

	Change in TotalBody Mass1			Fat Mass Change(kg)1	Percentage Changein Fat Mass1
2.4 mg beloranib (n=37)	-5.7%*			-5.0*	-9.8%*
1.8 mg beloranib (n=36)	-2.9%*			-2.5*	-4.5%*
Placebo (n=34)		+ 3.4	%	+ 2.6		+ 5.9	%

1Endpoint results shown are Least Squares mean values.*p<0.0001 compared to placebo

The most common adverse events (AEs) in this study were injection site bruising, aggression, and hyperphagia, generally of mild severity and transient in nature. Of these, only injection site bruising was notable as being reported more frequently in patients taking beloranib compared to placebo. There were a total of five serious adverse events (SAEs); aggression (placebo, 2.4 mg beloranib), ankle fracture (placebo), mental status change (1.8 mg beloranib), and pulmonary embolism (1.8 mg beloranib). Four patients withdrew due to adverse events in the 1.8 mg beloranib treatment group (abnormal behavior, anxiety, mental status changes, and pulmonary embolism) and two patients in the 2.4 mg beloranib group (injection site pain and psychotic disorder). Many of these adverse events, specifically psychiatric disorders, are commonly observed as background comorbidities in PWS patients. At the end of the randomized treatment period, there were no clinically significant abnormal patterns regarding laboratory values, vital signs, or electrocardiography (ECG) findings. As previously disclosed, across the completed trials comprising the beloranib clinical program, there has been an association of venous thromboembolic events reported in patients treated with beloranib versus placebo, including one fatal case of pulmonary embolism (1.8 mg beloranib) during the randomized portion of the bestPWS study that was reported in October 2015. No other venous thromboembolic events were reported during the blinded randomized portion of the bestPWS study. As previously reported, a second patient death associated with pulmonary embolism (2.4 mg beloranib) and two cases of deep vein thrombosis (1.8 mg and 2.4 mg beloranib) occurred during the open-label extension portion of the bestPWS study. No other deaths have occurred over the course of the beloranib program.

Zafgen plans to present to the FDA the data from the ZAF-311 clinical trial, and previously reported data from the ZAF-203 Phase 2b clinical trial of beloranib in obesity complicated by type 2 diabetes, as well as a proposal for a risk mitigation strategy for beloranib in PWS in an effort to resolve the full clinical hold the FDA placed on the beloranib IND in December 2015.

Source: Street Insider

Broad Street Alerts has not been compensated for the mention of _ZFGN__ and we do not hold any positions.

See Full Report below….

 

About Broad Street Alerts:

 

Big opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our

Members in the last 3 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49%

 

for our members.

 

 

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to

see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and

verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest

of the small-cap newsletters as the best in business. We know with a large following comes a large

responsibility as we have everyone from institutional investors to the beginner following our profiled

securities in our newsletters. This is something we take very seriously always seeking small cap growth

companies that have both near and long-term potential for our members.

 

***Get our small cap profiles, special situation and watch alerts in real time.

We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Report:

Research brokerage firms on Wall Street employ an army of analysts which dedicate the majority of their time analyzing stocks in their coverage universe. They issue Buy, Sell and Hold recommendations as well as earnings estimates and guidance. Out of the 10 analysts covering shares of Zumiez Inc. (NASDAQ:ZUMZ), 3 rate it a “Strong Buy”, 0 rate it a “Buy”, 11 are advising to Hold the shares and 0 are saying “Sell”. Each recommendation can be mapped to an integer using a 1 to 5 scale. Taking the average of the numerical ratings, the stock has a consensus recommendation of 2.57. This is based on a 1 to 5 scale where 1 is equivalent to a Strong Buy rating and 5 a Strong Sell.

Investors will be looking ahead to the company’s earnings report with is scheduled to go out on or about 2016-06-02. The Wall Street consensus is saying that the firm will report earnings of $-0.09 per share for the quarter. Analysts often update their models several times during the quarter leading up to the earnings period. The direction of the sentiment is an important indicator of where the Street sees the stock headed. In comparing to the same quarter last year, the firm posted earnings per share of $0.12. Most recently the firm posted quarter earnings of $0.53 against the Zack’s consensus estimate of $0.49. This represents a surprise factor of 8.16% or a numerical difference of $0.04.

The covering sell-side analysts also issue 12-month price targets on the stocks they cover. The 10 analysts weighing in on shares of Zumiez Inc. (NASDAQ:ZUMZ) have a consensus target of $21.8 on the stock. The standard deviation of all the estimates stands at $4.589 with the lowest being $17 and the highest sitting at $30.

 

Source: Clinton Financial

Broad Street Alerts has not been compensated for the mention of _ZUMZ__ and we do not hold any positions.